Gilead owes BMS $752 million for CAR-T toe-stepping

Gilead Sciences owes Bristol-Myers Squibb a whopping $752 million, after a Los Angeles jury concluded that Gilead’s Yescarta infringed on a patent held by Memorial Sloan Kettering, Juno Therapeutics and, by extension, BMS. 

BMS said in a statement that it’s pleased with decision; Gilead, of course, is not. It plans to appeal.

"Given that Kite independently developed Yescarta and assumed all of the risk in its discovery and development, we do not believe Sloan Kettering and Juno are entitled to any level of damages,” Gilead said.